Skip To The Main Content

Browse these ideas available for licensing that have the potential to improve lives while creating jobs to support and grow the region.


All technologies
 are listed as non-confidential technical summaries.

Technologies were generated by academic institutions, entrepreneurs, and corporations.

Click the Tech Search button below to have Whiteboard2Boardroom staff complete a personalized search for innovations to license from our research institution partners.

The most recent innovations from our partners are featured separately and organized by category. All listings are updated as new technology opportunities become available. 

For assistance in connecting with, or attaining further information on any of these technologies, please contact us.

Targeted Retinoblastoma Therapy

Researchers have developed two new aptamer platform technologies that can target and bind HMGA2 using specially designed targeted nanoparticles. HMGA2 has been shown to be upregulated in a large number of cancers, particularly retinoblastoma. These new platforms achieve intended therapeutic effects by penetrating the cellular bilayer.

BACKGROUND:
HMGA2 is an architectural transcription factor, a large protein that is responsible for the upregulation of oncogenic and tumor proliferative mechanisms. The protein HMGA2 has been highly associated with retinoblastoma, as well as other cancers. Controlling HMGA2 levels could lead to first effective treatment methods of retinoblastoma.

Retinoblastoma is a life threatening cancer that occurs in the eye and can spread to other parts of the body. Almost exclusively found in young children, current retinoblastoma treatments include photocoagulation, cryotherapy, chemotherapy, radiation therapy, or enucleation. To date, there is no minimally invasive treatments for retinoblastoma.

APPLICATIONS:
  • Retinoblastoma
  • Cancer prevention
  • Targeted cancer treatment

ADVANTAGES:
  • Minimally invasive
  • Minimal risk
  • Potentially less drug rejection
  • Cost-effective production


Additional Details

Owner

University of Missouri

Intellectual Property Protection

Pending Patent



Interested? Request More Information